{"entity":{"id":"nct07718490","kind":"trial","name":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab in colorectal cancer, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.","summary":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT07718490 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 43 participants, started 2025-09-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Adebrelimab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Investigator-assessed Objective Response Rate（ORR）. Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed metastatic colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07718490","url":"https://clinicaltrials.gov/study/NCT07718490"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07718490","phase":"2","setting":"A Multicenter, Prospective, Phase II Exploratory Study on the First-line Treatment of MSS/ PMMR-type Advanced Colorectal Cancer With Adebrelimab Combined With Simvastatin and Targeted and Chemotherapy","sponsor":"The First Affiliated Hospital with Nanjing Medical University","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07718490/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}